|
Valoración de DCF de Aclaris Therapeutics, Inc. (ACRS)
US | Healthcare | Medical - Diagnostics & Research | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Aclaris Therapeutics, Inc. (ACRS) Bundle
¡Ahorre tiempo y mejore la precisión con nuestra calculadora DCF (ACRS)! Utilizando datos reales de Aclaris Therapeutics, Inc. y supuestos personalizables, esta herramienta le permite pronosticar, analizar y valor (ACR) como un inversor experimentado.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.2 | 6.5 | 6.8 | 29.8 | 31.2 | 44.0 | 61.8 | 87.0 | 122.4 | 172.1 |
| Revenue Growth, % | 0 | 53.35 | 4.3 | 340.05 | 5.03 | 40.67 | 40.67 | 40.67 | 40.67 | 40.67 |
| EBITDA | -90.8 | -48.2 | -65.1 | -84.4 | -117.6 | -44.0 | -61.8 | -87.0 | -122.4 | -172.1 |
| EBITDA, % | -2148.97 | -743.52 | -962.28 | -283.53 | -376.22 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 1.6 | 1.3 | .9 | .8 | .9 | 6.8 | 9.5 | 13.4 | 18.9 | 26.5 |
| Depreciation, % | 37.52 | 20.43 | 13.65 | 2.68 | 2.76 | 15.41 | 15.41 | 15.41 | 15.41 | 15.41 |
| EBIT | -92.4 | -49.5 | -66.0 | -85.2 | -118.4 | -44.0 | -61.8 | -87.0 | -122.4 | -172.1 |
| EBIT, % | -2186.49 | -763.95 | -975.94 | -286.21 | -378.98 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 75.0 | 54.1 | 225.7 | 229.8 | 119.1 | 44.0 | 61.8 | 87.0 | 122.4 | 172.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .7 | .8 | .6 | .5 | .3 | 3.5 | 5.0 | 7.0 | 9.9 | 13.9 |
| Account Receivables, % | 16.65 | 11.91 | 9.21 | 1.63 | 0.95363 | 8.07 | 8.07 | 8.07 | 8.07 | 8.07 |
| Inventories | 5.0 | .0 | -34.2 | -12.2 | .0 | -3.6 | -5.1 | -7.2 | -10.1 | -14.2 |
| Inventories, % | 117.48 | 0 | -506.46 | -41.15 | 0 | -8.23 | -8.23 | -8.23 | -8.23 | -8.23 |
| Accounts Payable | 9.9 | 5.3 | 10.0 | 10.4 | 8.9 | 30.3 | 42.6 | 59.9 | 84.2 | 118.5 |
| Accounts Payable, % | 234.61 | 81.06 | 147.69 | 34.79 | 28.41 | 68.85 | 68.85 | 68.85 | 68.85 | 68.85 |
| Capital Expenditure | -1.6 | -.5 | -.3 | -.6 | -1.3 | -4.9 | -6.9 | -9.7 | -13.7 | -19.3 |
| Capital Expenditure, % | -38.16 | -6.99 | -4.56 | -2.03 | -4.19 | -11.19 | -11.19 | -11.19 | -11.19 | -11.19 |
| Tax Rate, % | 0.41307 | 0.41307 | 0.41307 | 0.41307 | 0.41307 | 0.41307 | 0.41307 | 0.41307 | 0.41307 | 0.41307 |
| EBITAT | -116.3 | -49.3 | -83.0 | -86.9 | -117.9 | -43.9 | -61.7 | -86.9 | -122.2 | -171.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -112.1 | -48.2 | -43.2 | -108.2 | -131.9 | -20.3 | -46.8 | -65.8 | -92.6 | -130.3 |
| WACC, % | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -292.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -133 | |||||||||
| Terminal Value | -3,917 | |||||||||
| Present Terminal Value | -3,012 | |||||||||
| Enterprise Value | -3,305 | |||||||||
| Net Debt | -39 | |||||||||
| Equity Value | -3,266 | |||||||||
| Diluted Shares Outstanding, MM | 70 | |||||||||
| Equity Value Per Share | -46.78 |
What You Will Get
- Real ACRS Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Evaluate various scenarios to assess Aclaris Therapeutics' future performance.
- User-Friendly Interface: Designed for professionals while remaining approachable for newcomers.
Key Features
- 🔍 Real-Life ACRS Financials: Pre-filled historical and projected data for Aclaris Therapeutics, Inc. (ACRS).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Aclaris's intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Aclaris's valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the prebuilt Excel template with Aclaris Therapeutics' data included.
- Step 2: Explore the pre-filled sheets and understand the key metrics.
- Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view recalculated results, including Aclaris Therapeutics' intrinsic value.
- Step 5: Make informed investment decisions or generate reports using the outputs.
Why Choose This Calculator for Aclaris Therapeutics, Inc. (ACRS)?
- Designed for Experts: A sophisticated tool tailored for analysts, CFOs, and industry consultants.
- Accurate Data: Aclaris Therapeutics' historical and projected financials are preloaded for precision.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance ensures a smooth navigation through the process.
Who Should Use This Product?
- Investors: Evaluate Aclaris Therapeutics’ valuation before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess financial forecasts.
- Startup Founders: Understand the valuation strategies of established biotech companies like Aclaris Therapeutics.
- Consultants: Provide expert valuation analyses and reports for client projects.
- Students and Educators: Utilize current data to learn and teach valuation practices in the biotech sector.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Aclaris Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), featuring parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models presenting intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to facilitate analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Aclaris Therapeutics, Inc. (ACRS).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions for easy result analysis.